Human exposure to phthalates and bisphenol A (BPA) can be assessed through urinary biomonitoring, but methods to infer daily intakes assume that spot sample concentrations are comparable to daily average concentrations. We evaluate this assumption using human biomonitoring data from Germany and the United States (US). The German data comprised three regional studies with spot samples and one with full-day samples analyzed for phthalate metabolites. The US data included: a study on DEHP metabolites and BPA involving eight persons supplying all urine voids (from which 24-h samples were constructed) for seven consecutive days; NHANES spot sample data on DEHP metabolites and BPA; and a regional study of children with 48-h samples analyzed for BPA. In the German data, measures of central tendency differed, but spot and 24-h samples showed generally comparable variance including 95th percentiles and maxima equidistant from central tendency measures. In contrast, the US adult data from the eight-person study showed similar central tendencies for phthalate metabolites and BPA, but generally greater variability for the spot samples, including higher 95th percentiles and maxima. When comparing children's BPA concentrations in NHANES spot and 48-h samples, distributions showed similar central tendency and variability. Overall, spot urinary concentrations of DEHP metabolites and BPA have variability roughly comparable with corresponding 24-h average concentrations obtained from a comparable population, suggesting that spot samples can be used to characterize population distributions of intakes. However, the analysis also suggests that caution should be exercised when interpreting the high end of spot sample data sets.
INTRODUCTION
The emergence of biomonitoring has ushered in a new era in the characterization of human exposure to chemicals in the environment. Prior to the 1990s, the study of human exposure to chemicals in the environment mainly focused on understanding intakes of different chemicals through characterization of exposure media concentrations and exposure contact rates. 1 Regional and national population surveys to determine the presence of chemicals in the body gave exposure assessors another, arguably more powerful, measure of exposure and internal dose. In these general population surveys, chemicals measured in blood tend to be those which are persistent in the environment and in the body, and the measurements typically represent the accumulation of the chemical over many years of exposure. Other chemicals are measured in urine, and they represent a different pattern both in persistence and exposure. These contaminants tend not to persist in the body, with half-lives on the order of days and hours, and are primarily excreted in urine. Exposure might be associated with identifiable events, as might be the case with the detection of pesticide metabolites in urine after pesticide application, or exposure might be ubiquitous and less understood. Such is the case with phthalates and bisphenol A (BPA).
Although detection of phthalate metabolites and BPA in urine prove that exposure occurs, the measurement of urinary metabolites does not provide information on route of exposure, or the rate of overall intake which resulted in the measured concentrations. However, many studies have developed estimates of daily intakes from the urinary concentrations of phthalate metabolites and BPA in spot samples, mainly using what is termed the ''creatinine-correction'' approach. This method takes advantage of the common practice of measuring creatinine, along with the target compounds, in a spot sample. Although measurement of creatinine is primarily done to normalize concentrations across individuals (i.e., to avoid issues which occur because urine volumes are a function of hydration and can result in high or low concentrations not reflective of chemical excretion), a creatinine-adjusted concentration in urine (mass of chemical divided by mass of creatinine) is also used to estimate daily intake. This simple back-calculation method takes advantage of relationships between a spot sample excretion of creatinine and total daily creatinine excretions. Assuming consistent daily intakes of a contaminant, a urine sample excretion can be related to a daily excretion of that contaminant based on the fraction of total daily creatinine excretion in that urine sample. A critical assumption in this approach is that the creatinine-adjusted concentration of a contaminant in a spot urine sample is equal to the contaminant daily average concentration in urine. However, given their first-order kinetics with half-lives in the order of hours (B5 h to 12 h 2--4 ), peak concentrations of DEHP metabolites and BPA occur in urine shortly after exposure, with decreasing concentrations several hours after exposure. 2, 5, 6 These peak concentrations could be mistaken to imply high daily exposures when using the creatinine-correction approach, and conversely, the lower concentrations could be mistaken for low daily exposures. Ideally, one would like full day (24 h) average concentrations to use in a creatinine-correction model, but such data are rarely available for large population surveys.
For compounds with short half-lives (on the order of hours), the variability in concentrations seen in a population of 24-h samples from a specific group of individuals will inevitably be less than the variability seen in a population comprised of all the individual urine samples from that same population. However, most surveys only take a single sample during a day, and consequently may miss some of the high concentrations that would be seen in their sample population if they sampled all urine events over the course of a day (or longer) from those individuals. The purpose of this study is to evaluate the comparability of spot urinary concentrations of phthalate metabolites and/or BPA obtained from a specific population, with the 24-h average urinary concentrations of these compounds obtained from a comparable population. If the two distributions are reasonably comparable, then one can use the creatinine approach for studying the distribution of intakes within a population with an acceptable degree of certainty, at least with regard to the urine-concentration term. Spot and long-term (24-h and 48-h) sample sets analyzed for phthalate metabolites and BPA were retrieved for this examination. Measures of central tendency and spread were examined within these populations. Additionally, statistical tests were applied to paired spot and long-term data sets to determine whether the two data sets could have come from the same distribution.
MATERIALS AND METHODS

Study Descriptions
Characteristics of the data sets used in this study are summarized in Table 1 , with further details provided in the Supplementary Material. Three German data sets using spot urine samples included surveys of 45 adults in 2007 in Bochum, 7 85 adults in 2002 in Erlangen, 8, 9 and 102 adults in 2005 in Bavaria (the latter data have not been published, but a description of the larger study of measurements from 1005 individuals from which a subset of 102 were analyzed for phthalate metabolites can be found in Kutting et al.) 10 To compare with these data sets was a set of 712 students, aged 20--29, who provided 24-h urine samples between 1988 and 2003 to the Environmental Specimen Bank of the Federal Environmental Agency of Germany. A description of this database and a summary of partial results can be found in Wittassek et al. 11 and the website for the Environmental Specimen Bank: http://www.umweltprobenbank.de/en/documents. All urine samples from these German data sets were analyzed for di-2-ethylhexyl phthalate (DEHP) metabolites: mono-(2-ethylhexyl) phthalate (MEHP), mono-(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), and mono-(2-ethyl-5-oxohexyl) phthalate (MEOHP); for the mono-ester metabolite of di-n-butyl phthalate (DnBP), mono-n-butyl phthalate (MnBP); for the mono-ester metabolite of di-isobutyl phthalate (DiBP), mono-isobutyl phthalate (MiBP); and for the mono-ester metabolite of butylbenzyl phthalate (BBzP), mono-benzyl phthalate (MBzP). In the spot sample data sets from Bochum and Erlangen, values below the limit of detection (LOD) were substituted with zero. In the spot sample data set from Bavaria and the 24-h urine data set from the Environmental Specimen Bank, values below the limit of quantification (LOQ) were substituted with LOQ/O2.
A data set from Atlanta, Georgia in the United States included eight adults, four women, and four men aged 25--59 years of age, who provided a complete set of urine spot samples (n ¼ 427) over a consecutive 7-day period in 2005. 12 Each sample was analyzed for the DEHP metabolites, MEHP and MEHHP as well as for BPA, and 24-h concentrations were constructed from the spot sample concentrations. First morning voids, defined as the first urination event after 0500 hours, were culled from the full set of spot samples. To compare with the urinary concentrations of all spot samples, first morning void spot samples, and 24-h samples from the Atlanta data set, we used the 2005--2006 National Health and Nutrition Examination Survey (NHANES) data on these metabolites for adults (418 years). This cycle (2005--2006 ) was chosen for comparability to the timing of the Atlanta study. NHANES participants provided urine samples throughout the day (rather than first morning voids), and phthalate metabolite concentrations are available for a random 1/3 sample of participants. In both the Atlanta data set and the NHANES, values below the LOD were substituted with LOD/O2.
BPA urinary concentrations in 48-h samples were determined as part of the Children's Total (Aggregate) Exposure to Persistent Pesticides and Other Persistent Organic Pollutants (CTEPP) study. 13 For the present study, we used a subset of CTEPP 48-h urine samples collected during a 2-day period in 2000--2001 from 110 children, ages 23 to 64 months, including 81 children from Ohio and 29 from North Carolina. The 48-h samples (one per child), constructed by pooling six spot samples (3 each day, from the morning, afternoon, and evening), were analyzed for total (free plus conjugated) BPA. To compare with this BPA data set, we retrieved the 2003--2004 NHANES BPA results for children, aged 6--11 years. This cycle and age range were chosen for comparability to the CTEPP study, given that 2003--2004 was the first cycle in which BPA was measured, and that measurements are only available for participants aged Z6 years. Values below the LOD were substituted with LOD/O2.
All studies contained concentrations reported either on a volume basis (ng/ml) or a creatinine-adjusted basis (ng contaminant/mg creatinine). We conducted all of our analyses on volume-based concentrations. Although hydration certainly affects dilution and volume-based concentrations, and creatinine-based concentrations are thought to address issues with hydration, creatinine-based concentrations themselves may not account for differences in race and nationality. The Supplementary Material contains an exercise showing that the variability in volume-based concentrations is similar to that of creatinine-based concentrations, using the DEHP-metabolite data from the Atlanta and NHANES data sets.
Protocols for these studies were reviewed for human subject considerations within the institutions, which conducted the studies, and all raw data used in this study were deidentified.
Statistical Methods
All statistical analyses were performed using SAS/STAT software, Version 9.2. The distributions of all of these population data sets were characterized by calculating measures of central tendency (geometric mean (GM), median) as well as spread (geometric standard deviation (GSD), interquartile range) and extreme values (95th percentile, maximum). For NHANES only, weighted statistics were derived using weights supplied by the National Center for Health Statistics. For the CTEPP data, there was one outlier, a child with a BPA-urine concentration 4200 ng/ml. Because this value was many times greater than the next highest value (39 ng/ml), we treated this result as an outlier and did not use it in the statistical analyses.
Further statistical tests were used to evaluate the comparability between concentrations derived from a population of spot samples and concentrations derived from a comparable population of 24-h samples (i.e., those that might be obtained from the same population). It should be noted that such testing is most appropriate for the Atlanta data set, because the spot samples and the 24-h samples came from the same participants, over the same time period. In contrast, it is less meaningful to compare any of the concentrations derived from the German spot sample data sets with the concentrations derived from the German 24-h samples, because they represent different people: the general adult population versus 20-to 29-year-old students, from different parts of Germany, different collection years, different time of day for sampling, and most importantly, different exposure patterns. Despite these limitations, these tests give additional insight as to whether the distributions are similarly shaped, so we compared the results using German 24-h samples with each of the German spot samples, the Atlanta 24-h samples with the Atlanta spot samples, and the CTEPP BPA 48-h data set with NHANES data on BPA. Urine concentrations for each metabolite were log base 10 transformed before performing these tests, in order to more closely approximate normality; we also include results from these tests with no transformation applied, in the Supplementary Material. As the distributions of phthalate metabolite concentrations in urine may not meet normality assumptions (especially given limited sample sizes) even after appropriate transformation, we compared distributions using non-parametric methods. The equality of the distributions was compared using the Cramer-von Mises criterion, and the variances of the distributions were compared using Levene's test. The Cramer-von Mises criterion compares two empirical distributions by ranking the values in the two distributions separately, then in combination, and comparing the resulting rank orders ---subsequently, values closer to zero indicate less difference (more similarly shaped distributions). It is considered more robust than other methods (such as the Kolmogorov--Smirnov test), when differences in location are expected. Levene's test assesses equality of variance between two sample sets, using the squared deviation of values from the group means. As Levene's test gives information about the equality of the spread of the distribution without assuming similar central tendencies, it is likely the most informative and appropriate test for use in comparing the German 24-h samples with the German spot samples and the BPA data sets. As noted above, the differences in the populations and exposure patterns in the German data may lead to differences in measures of central tendency, but it is possible to assess whether the distributions from each population have a similar degree of variability.
For the Atlanta data set, we also created a series of bootstrap data sets from the Atlanta spot sample data. This was done by randomly selecting one spot sample per person per day, for a total of 56 values; this process was repeated 1000 times to generate 1000 data sets, each with one spot sample per person per day (i.e. 56 samples in each). To characterize the overall results from this bootstrap sample, the median values of the statistical measures calculated for each of the 1000 data sets were calculated and presented. The purpose of constructing the bootstrapped data sets is primarily to assess the right tail (high-end) of a distribution of spot samples when one obtains only one sample per person per day. If one samples all daily urine events for a given population, such as the 427 spot samples of the Atlanta data set, one sees the full extent of the right tail. On the other hand, if each individual provided one sample per day at random times, the shape of the distribution and in particular, the characterization of the right tail is unknown, but likely would be different than the right tail of the full sample set of 427 spot samples. The bootstrap attempts to characterize this difference between all samples versus one sample taken at random times during a day. However, given the limited sample size and skewed nature of the data, the estimation of upper percentiles (such as the 95th) is challenging.
14 In looking at urinary metabolite concentrations in the general population, there is generally a long right tail ---that is, most of the data are clustered in the lower range and there are a few persons with much larger values ---which may lead to bias in bootstrap estimation of the upper percentiles. To address this issue, we estimate the 95th percentile in the bootstrapped samples using both the empirical distribution function with averaging (the most widely used method, and the default option in SAS) and the weighted average (i.e. linear interpolation between ranked values). 15 This weighted average approach should provide a more robust estimate for comparison. 
RESULTS
The results are described in four sections: the German data on phthalate metabolites, the US data on phthalate metabolites, the US data on BPA --Adults, and the US data on BPA -Children.
Figures 1--5 are box and whisker plots showing the median, the interquartile range, and the 95th percentile, of a given distribution. The results of the statistical tests comparing pairs of studies are displayed in Table 2 . Additional results are included in tables in the Supplementary Materials.
German Data on Phthalate Metabolites Figures 1 and 2 depict the distribution of the measured phthalate metabolite concentrations for the four German populations (three spot sample and one 24-h data set). Adults from the Bochum study showed the lowest concentrations and those from Erlangen, the highest. The difference in central tendency measurements of the six phthalate metabolites between these two populations ranged from a factor of about 5 to almost 20. However, although the results show different central tendencies, and correspondingly higher 95th percentile and maximum values, the GSDs for all populations and metabolites seem to vary narrowly from less than the GM to well within a factor of 2 above the GM. The 25th percentile of all four data sets was about half the median and the 75th percentile was about twice the median. The 95th percentile was B3 to 6 times the median. The 24-h concentration data for the DEHP metabolites had spread comparable to the spot samples, but the 24-h concentration data had the most spread for MnBP, MiBP, and MBzP, including the highest maxima. For example, the maximum 24-h measurement of MnBP (2090 ng/ml) was about twice as high as the highest maximum value found in the spot samples: 1256 ng/ml from the Erlangen samples. We believe it's possible that a contributing factor to 24-h samples showing equal and maybe higher spread than the spot samples is the much larger sample size (n ¼ 712) of the 24-h data set compared with the spot sample data sets (all n o100). Table 2 shows the statistical measures comparing the distribution of concentrations from 24-h samples to the distribution of concentrations from the three sets of spot samples. In nearly all cases, the Cramer-von Mises criterion was quite close to zero (ranging from 0.0003 to 0.016), indicating a similar overall shape of the distributions. When comparing variance, there were a few groups for which Levene's test indicated significantly different variance: between the 24-h samples and the Bavaria spot samples (all but MBzP) and between the 24-h samples and the Erlangen spot samples for two DEHP metabolites (MEOHP, MEHHP). These patterns are reflected in the descriptive statistics ---for example, the maximum concentrations for MEOHP and MEHHP were much higher in the Erlangen data compared with the 24-h data. Figure 3 depicts the distribution of the two measured DEHPmetabolite concentrations for the NHANES and four permutations of the Atlanta data set. The central tendency measures of median and GM for these data sets were very similar, unlike the German data. Four of the data sets are permutations from the same study, and thus it is expected that their measures of central tendency would be similar, but the similarity with the national NHANES data does suggest that this focused data set characterized exposures that, at least for their central tendency, were similar to national tendencies. However, unlike the German data, there was generally a greater amount of variability when comparing the concentrations from all spot samples, to the 24-h averages.
US Data on DEHP Metabolites
The rank order from most to least variable is as follows: NHANES 4all spot samples 4bootstrap spot samples 4first morning voids 424-h samples. NHANES had the highest maximum, about 4 to 10 times higher than the maximum from the Atlanta spot samples. At least one reason for this disparity between NHANES and the Atlanta data sets is sample size: over 1600 adults each supplying a Figure 1 . Box plots of DEHP metabolites from four German surveys (median and 95th percentiles displayed on graphs).
spot sample for NHANES, compared with only eight individuals in the Atlanta data. Although these eight individuals supplied 427 spot samples, they still represent lifestyles and exposure patterns of only eight individuals, all living in one city.
Within the four groupings of the Atlanta data set, the variability in concentrations from the 24-h samples and the first morning void spot samples were comparable, and both lower than the variability in the other two groupings (all spot samples and bootstrap spot samples). The maximum for the 24-h and first morning voids were 2 to 4 times lower than the maxima for the other two permutations.
It is interesting that although the 95th percentile values for the 24-h and NHANES data sets were virtually identical, the maximum for NHANES was over an order of magnitude higher than the maximum of the 24-h samples. Again, this is likely owing to the much larger sample size of NHANES, as well as different distribution of sampling times (and fasting protocols) in the NHANES. But it does highlight an intuitive expectation: a 24-h sample will dampen the high as well as low concentrations that arise from spot samples from phthalates and related contaminants for which exposure is frequent and almost a daily event, and elimination of metabolites in urine is in the order of hours. The highest concentrations are near the time of exposure and low concentrations are found many hours after exposure. But when assessors have a large database such as NHANES, with which to study exposures, the important question remains: do adults at the high end of the concentration distribution in NHANES experience a much higher daily exposure than might be implied had all of them supplied 24-h instead of spot samples?
Possibly the best comparison we can make to answer this question is the comparison between bootstrapped spot samples and 24-h samples from the Atlanta cohort. Here the comparison is between a 24-h sample and a random sample taken from the same person on same day. Proportionately, the ratio of the GSD to the GM is about twice as high for the bootstrapped as compared with the 24-h samples. The 95th percentile for the bootstrapped sample metabolite concentrations is about 15--20% higher than the 95th percentile for the 24-h samples (using a weighted average to estimate the 95th percentile in the bootstrapped samples), and the maxima are about twice as high for the bootstraps as compared with the 24-h samples. All of these measures suggest that the high-end of a population of spot samples tends to be higher than that of a population of 24-h samples. A comparison between the bootstrapped data and all 427 spot samples from Atlanta also show trends of note. In general, the measures of central tendency (GM, median) and spread (GSD, interquartile range) of the bootstrapped samples were similar to the full set of 427, from which the bootstrap was derived, but the maximum was much lower. This finding is logical ---when randomly selecting from each day, invariably all of the 1000 bootstrap data sets of 56 daily spot samples will miss several of the high concentrations that are incorporated into the analysis of all 427 samples.
For the statistical tests of distribution comparability, similar results to the comparison of German 24-h and spot samples were found for the Atlanta data ( Table 2) . Of all the data sets used, the Atlanta data set is the only one with 24-h and spot samples from the same individuals; thus, it is more appropriate to test whether the spot samples are from the same distribution as the 24-h values. The Cramer-von Mises criterion was close to zero for all comparisons (ranging from 0.002 to 0.005), indicating similar overall shape of the distributions. Levene's test indicated different variance for MEHHP 24-h and spot samples (P-value ¼ 0.008), but borderline similarity in variance for MEHP (P-value ¼ 0.06).
We also evaluated the distribution of MEHHP and MEHP urinary concentrations on a creatinine-corrected basis (results in Supplementary Material). The results were quite similar to those found using a volume basis in magnitude and variability, so that the overall patterns were preserved when comparing across data sets. For example, the GM for MEHP ranged from 2.96 (NHANES) to 6.44 (Atlanta 24-h) mg/g creatinine; the GM for the spot and bootstrapped spot samples was intermediate (4.73 and 4.39 mg/g creatinine, respectively) and for each data set the GSD was similar in magnitude to the GM. Also, similar to results using a Figure 4 . Box plots of BPA from US surveys including four from the Atlanta survey (all spot, bootstrapped spot, first morning void, and constructed 24 h) and NHANES (median and 95th percentiles displayed on graphs). volume basis, the maximum values were lowest in the Atlanta 24-h samples (76.6 mg/g creatinine) and highest in the NHANES data set (707.23 mg/g creatinine).
US Data on BPA --Adults Figure 4 depicts the distribution of BPA concentrations for the NHANES and four permutations of the Atlanta data set. Many of the trends noted above for the US data on DEHP metabolites are seen here as well. The central tendency measures of median and GM for these data sets were very similar, rounding off to 2 or 3 ng/ml. NHANES data showed the most spread in concentrations, but this spread showed up mostly above the 95th percentile. For NHANES, the 95th percentile was about 11 ng/ml compared with the range from 7 to 10 ng/ml for the four groupings of the Atlanta data set. However, the maximum was 383 ng/ml compared with the maximums between 12 and 50 ng/ml for the four groupings of the Atlanta data set. Unlike the DEHP-metabolite data discussed above, the first morning void concentrations of BPA showed a variability that better matched other spot sample groupings than the 24-h samples. The interquartile range of the 24-h samples was the narrowest at 1.5--3.2 ng/ml, whereas it was wider for first morning voids at 1.3--5.0 ng/ml. The 95th percentile for the 24-h samples was 7.0 ng/ml, whereas it was 9.1 ng/ml for the first morning voids, similar to the other spot-sample groups, 8.6 ng/ml for all spot samples and 9.9 ng/ml for the bootstrap samples. When using statistical tests to evaluate the comparability of 24-h and spot samples in the Atlanta BPA data, the pattern of results was similar to those found for the phthalate metabolites in this data set ( Table 2 ). The first morning void spot samples were more similar to the 24-h samples than were the group of all spot samples in terms of shape (Cramer-von Mises criterion values of 0.0002 and 0.002, respectively). The variability was also more similar between the first morning void and 24-h samples (Levene's P-values of 0.02 and 0.003, respectively). Figure 5 depicts the distribution of BPA concentrations for the NHANES and the CTEPP 48-h data sets from NC and OH. The CTEPP data showed very similar distributions between urine samples collected from children in NC and OH. When comparing the urinary BPA concentrations in the NHANES data with those from the CTEPP data, the measures of central tendency were quite similar, although the GMs and medians were slightly higher among CTEPP children compared with the NHANES data (children aged 6--11 years). The interquartile range and 95th percentile values were also similar among the three groups. The CTEPP data show a shift to the right compared with NHANES: all of these measures are about 1--2 ng/ml higher than their NHANES counterparts. This could be the result of the demographic differences in the two data sets --the NHANES captured a national sample of 6--11 year olds whereas the CTEPP study targeted a non-random selection of 2--5 year-olds in NC and OH. The 48-h samples had a very similar GSD compared with the NHANES data, with values ranging from 2.40 to 2.68 ng/ml. The NHANES data had a somewhat higher maximum value (46.1 ng/ml) compared with the 48-h data (maxima of 37.4 and 38.6 ng/ml for NC and OH, respectively). Summary Some dissimilar trends emerged from the US and German data sets and their long-term and spot samples. The 24-h DEHP data from the Atlanta data set show a narrower spread than the corresponding spot samples. There, the spot samples showed variability that was dampened when averaging over 24-h periods. In contrast, the German 24-h phthalate metabolite concentrations showed a much wider range and variability as compared with the German spot samples from different individuals and locations. The US BPA data are more similar to the German data, in that they show a spread and variability that appears quite comparable with the spot samples. Reflecting the similarity in the amount of spread and measures of central tendency for these BPA data sets, statistical tests indicated no significant differences between the CTEPP data and the NHANES data when comparing distributions in terms of overall shape, or variance (Table 2) .
US Data on BPA --Children
DISCUSSION AND CONCLUSIONS
Researchers have used spot sample surveys to infer daily intakes of key contaminants. As discussed earlier, simple methods to backcalculate daily intakes from spot samples rely on the assumption that the spot sample concentration is a good surrogate for the 24-h average concentration. The ideal data set to examine this question would be one which includes a large number of individuals who provided a 24-h sample as well as a spot sample randomly taken on the day of the 24-h sample. We found one data set that had this feature, but it included only eight individuals, so any generalizations or conclusions from these data must be made cautiously. We believe a sample size much larger than eight would be necessary to capture different patterns of exposure. How ''large'' such a sample size is obviously an issue of debate; 100 individuals would be better than eight, but 1000 would be even better. If each of the 712 individuals in the German data set provided a spot sample during the day in which the 24-h sample was provided, then a fairly rigorous analysis could be done. Without this luxury, we sought several diverse individual data sets including spot samples and 24-or 48-h samples including different contaminants (phthalates and BPA) and different age groups (children to adults).
Besides our analysis, there are three published studies that looked at the differences between urinary concentrations of phthalates and other non-persistent contaminants in spot and 24-h samples. Frederiksen et al. 16 examined the volume-based (not creatinine-based) concentrations of phthalate metabolites in 1st and 2nd morning samples as well as 24-h samples from 129 healthy Danish children (n ¼ 103, 6--16 years of age) and young adults (n ¼ 26, 17--21 years of age). They measured metabolites of DEP, DBP, BBzP, DEHP, and DiNP. The highest concentrations of all phthalate metabolites were in the 1st morning urine sample, and on a mass basis, between 40% and 48% of daily excretions were found in this first morning sample. The 2nd morning voids were also higher than the 24-h averages, but by a lesser amount than the 1st morning voids. Although not obtaining other spot sample data, it can be surmised that, for this population, the morning samples captured the daily high concentrations for phthalates.
Li et al. 17 evaluated the variability in urinary concentrations of mono-hydroxy polycyclic aromatic hydrocarbons (OH-PAHs) on the same group of eight persons and 427 samples from the Atlanta data set studied here for BPA and DEHP metabolites. Among the 427 samples, they looked at the concentration of OHPAHs in the population of first morning voids (n ¼ 56), constructed 24-h voids (n ¼ 56) and over all samples (n ¼ 427). They found that the first morning voids had the highest concentrations, with GMs and medians roughly 1.2 and 1.5 times higher than analogous metrics for constructed 24-h samples. Interestingly, however, the GMs and medians were similar or slightly lower over the population of 427 samples as compared with the constructed 24-h samples for the different OH-PAHs. This might suggest that for OH-PAHs, spot sample concentrations taken at random times of the day would yield information on the central tendencies that is comparable with the central tendencies derived from a distribution of 24-h samples.
In the third study, Scher et al. 18 collected first morning voids and 24-h samples from farmers and their children potentially exposed to chlorpyrifos. They measured 3,5,6-trichloro-2-pyridinol (TCP), a chlorpyrifos metabolite, in the first morning void the day following application of chlorpyrifos to a nearby agricultural field, and in the corresponding 24-h void for the day following application. This strategy was employed because toxicokinetics suggested that a peak concentration in urine would appear roughly 24 h following an exposure. As expected, the first morning void concentrations of TCP were higher than those estimated from the 24-h samples.
All of these studies showed evidence that the first morning void might be higher than a 24-h average, whereas the study on PAH metabolites additionally showed that random samples taken throughout the day might show similar central tendencies as compared with 24-h samples. The study on chlorpyrifos was targeted based on a likelihood of recent exposure, and an expectation that the peak concentration in urine might occur 24 h after this exposure, about the time of the first morning void. For this reason, it is not unexpected that the first morning void had higher concentrations than the 24-h samples. For the study on phthalates and children/young adults, one consideration perhaps is that these younger individuals do not wake up and urinate at night as frequently as older adults and often not at all, such that the first morning voids include all phthalate metabolites that would have migrated to the bladder overnight, and as a result, their first morning void might well have higher concentrations as compared with the first morning voids of adults.
Two other studies have also looked at the relationship between urinary concentrations of BPA and phthalates over time, although in a somewhat different way. Mahalingaiah et al. 19 examined the urinary concentration of BPA in spot samples taken from 82 subjects seeking infertility evaluation and treatment, and had multiple spot samples from a subset of individuals. Although the authors did not examine correlation of BPA concentrations in spot samples taken during the same day, they did look at how well a single spot sample characterized long-term trends in the full set of spot samples. They concluded that a single spot sample had good ability to identify individuals in the highest tertile of exposure, and that predictive power improved when two samples from the same day were used. Similarly, Teitelbaum et al. 20 evaluated urinary concentrations of phthalate metabolites, phytoestrogens and phenols among 35 minority children over a 6-month period, to determine how well a single spot sample characterized long-term trends. They also concluded that a single spot sample was reliable in ranking subjects according to tertile of all the analytes studied. These studies addressing a different aspect of the question, on the variability in spot versus long-term sampling, also provide confidence that a single spot sample may recapitulate trends in exposure.
In our study, we found that first morning voids of the two DEHP metabolites and BPA in the Atlanta cohort of adults showed a narrow range of variability, comparable with the 24-h samples, and lower than the variability of all spot samples. The central tendencies of the first morning voids were comparable with 24-h and other spot samples, including NHANES samples, although the first morning void of MEHHP was a bit higher. This is also what Preau et al. 12 found for MEHHP in the same data set. Aylward et al. 21 studied the issue of extrapolating spot versus 24-h concentrations of DEHP to daily intakes directly using the Atlanta cohort. They determined daily intakes in two ways: from concentrations in spot samples using a creatinine-correction approach and from concentrations in 24-h constructed averages on a volume-basis approach. They found that intakes determined from concentrations in spot samples ranged from 20--300% of intakes determined from 24-h average concentrations. From their analysis, it is clear that application of the creatinine-correction approach can underestimate as well as overestimate daily intakes for a given individual. But what is the expectation of over or under estimation over a full population? As mentioned often, this Atlanta cohort contains only eight adults in one city, so one must be cautious about drawing any conclusions from an analysis of their data. This issue is not only a matter of general interest, but it takes on additional importance when the extrapolation is used to comment on population health risk. Health and/or regulatory benchmarks for phthalates and BPA are expressed on an intake basis. Intakes have been derived from concentrations in spot samples using the creatinine-correction approach, and the upper ends of the population distributions have been examined for their relationship to these intake-based benchmarks. Koch et al., 22 for example, measured spot urine concentrations of metabolites of six phthalates in 111 German children aged 5--6 years during a mandatory health examination for entrance into the education system, and determined each child's intake of each phthalate using the creatinine-correction approach. They compared the intakes of each phthalate with the Tolerable Daily Intake (TDI) for that phthalate, and also developed a cumulative TDI (TDI CUM ), by adding the ratio of the individual child's intake divided by the TDI for each phthalate, that is, the sum of (intake PH /TDI PH ) over the six phthalates. They found that about 2% of the children (2 of 111) exceeded the TDI for DnBP, 1% approached the TDI for DEHP, and 24% exceeded the TDI CUM for the sum of DEHP, DnBP, and DiBP. In a general population study entailing 85 German individuals, Koch et al. 8 measured four metabolites of DEHP and, from these, determined daily intakes using the creatinine approach. They found that 10 of 85 individuals had intakes that exceeded the European Union TDI value (at the time of publication in 2003) of 37 mg/kg per day, and that 26 of 85 individuals had intakes higher than the US Reference Dose (RfD) of 20 mg/kg per day. One can question whether the individuals identified in these studies actually had an intake on the day of sampling that exceeded the TDI or RfD for the given phthalate. However, if the distributions of spot and full-day urinary concentrations are similar, one may infer that B2% of children in the region of Germany studied, would experience an exposure to DnBP greater than the TDI on any given day.
It should be noted that health benchmarks including the RfD and the TDI are often developed assuming a long-term, and not a single day, of exposure. The studies summarized above made observations based on a surveys of single-day samples. As well, the analysis in this paper looked only at inferences made from single spot samples taken during one day. As noted earlier, there has been some work on longitudinal variability ---whether a high concentration on a single day from an individual suggests ongoing elevations for that individual, a rare occasion, or something in between.
19,20 Preau et al., 12 for example, did examine day-to-day variability in DEHP metabolites from the Atlanta cohort and found substantial variability from this perspective.
For short-lived compounds such as phthalates and BPA, it is expected that the variability in concentrations seen in a population of 24-h samples from a specific group of individuals will, by definition, be less than the variability seen in a population comprised of all the individual urine samples from that same population. We saw this when we were comparing the 427 samples in the Atlanta cohort with their 24-h samples. However, one does not take all the urine samples in exposure surveys such as the NHANES; one takes only a single sample during a day. Given this fact, it is easy to envision that a spot sample survey will miss some of the high concentrations that would be seen in their sample population, if they sampled all urine events over the course of a day (or from several days), from those individuals rather than just one sample. In the same way, a population of 24-h samples might very well characterize some of the days with high exposures that are not captured in spot samples (e.g., if the individual who had high exposure had given a spot sample before the exposure occurred). These are the issues we attempted to investigate.
We recognize that an optimal data set is simply unavailable to address this question fully. The Atlanta data set best meets the criteria, and perhaps the most direct analysis is that comparing the 56 person-days of 24-h samples to the bootstrapped data sets of 56 person-days of individual spot samples. Generally, we found that the 24-h samples had less variability than the bootstrapped samples, as measured by spread around the central tendency, a lower 95th percentile, and a lower maximum concentration. When studying this question with less ideal data sets (i.e., non-matching 24-h and random spot samples), we did find variability in longterm samples that more closely matched the variability in spot samples. Specifically, the spread of the interquartile range, and the location of the 95th percentile and maximum concentration in relation to the median, were similar in the German data on phthalates and in the BPA data in children. This is probably the extent of the observations one can make, given that the long-term samples and spot samples came from different populations.
In conclusion, the analysis here suggests that given the limited data available to support such comparisons, concentrations of phthalate metabolites and BPA in spot urine samples on a population basis have variability reasonably comparable with 24-h urine concentrations of the same compounds on a population basis. This lends credibility to the use of spot sample surveys of phthalates and BPA to infer roughly approximate distributions of daily intakes within a population, and then to examine those distributions for trends. The caveat we offer to this generality is that caution should be exercised when using the high-end of spot sample surveys to characterize a high-end of daily intakes, particularly when the high-end of intakes appears close to health and regulatory intake-based benchmarks.
